Vivus in brief
Vivus is an unlisted company in the Biotechnology industry, based in Mountain View, USA. It was founded in 1991. In the year to December 2019 it had sales of $70 M and a net loss of $32 M.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Vivus
Vivus (OTCID Basic: VVUSQ) is a small pharmaceutical company headquartered in Campbell, California that specializes in obesity, sleep, and sexual health. Vivus developed Avanafil, an erectile dysfunction drug that has completed Phase 3 clinical trials. The drug has been approved for use by the Food and Drug Administration, and is sold under the trademark name Stendra. Stendra is the first and only oral erectile dysfunction treatment approved to be taken approximately 15 minutes before sexual activity.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Vivus timeline
- 1991
- 🏁· approximateFounded
- 1996
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
Events of Vivus from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Vivus
- Acquisitions and changes
- Delisted: it ended its SEC registration (Form 15) on 8 January 2021.
Market cap history
Not enough history yet.
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -45.2%
- Operating margin
- -15.7%
- Return on equity
- —
- Liabilities / assets
- 131.7%
- Net debt
- $209M
- Revenue growth
- +7.2%
- R&D / revenue
- 15.0%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2019 | $70M | +7.2% | $-11M | $-32M | -45.2% |
| Dec 2018 | $65M | -0.5% | $-3M | $-37M | -56.8% |
| Dec 2017 | $65M | -47.4% | $3M | $-31M | -46.7% |
| Dec 2016 | $124M | +30.2% | $56M | $23M | 18.8% |
| Dec 2015 | $95M | -16.4% | $-60M | $-93M | -97.6% |
| Dec 2014 | $114M | +40.8% | $-51M | $-83M | -72.4% |
| Dec 2013 | $81M | — | $-155M | $-174M | -215.2% |
| Dec 2012 | — | — | $-140M | $-140M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2019 | $-30M | $0M | $-31M | $-2.96 | — |
| Dec 2018 | $-24M | $0M | $-24M | $-3.48 | — |
| Dec 2017 | $-16M | $0M | $-16M | $-2.89 | — |
| Dec 2016 | $38M | $0M | $38M | $2.22 | — |
| Dec 2015 | $-46M | $0M | $-47M | $-0.90 | — |
| Dec 2014 | $-38M | $0M | $-38M | $-0.80 | — |
| Dec 2013 | $-135M | $2M | $-137M | $-1.72 | — |
| Dec 2012 | $-132M | $2M | $-134M | $-1.42 | — |
SEC filings
- Nov 16, 20208-KCurrent reportOther events
- Jul 13, 20208-KCurrent reportListing notice · Regulation FD disclosure
- Jul 7, 20208-KCurrent reportMaterial agreement · Bankruptcy · Directors or officers changed · Regulation FD disclosure
- Jun 19, 20208-KCurrent reportRegulation FD disclosure
- Jun 19, 2020S-1/AIPO registration (amended)
- Jun 9, 2020S-1IPO registration
- Jun 8, 2020S-1IPO registration
- Jun 2, 20208-KCurrent reportMaterial agreement · Regulation FD disclosure
- May 8, 20208-KCurrent reportResults of operations
- May 6, 20208-KCurrent reportResults of operations
- May 6, 202010-QQuarterly report · period to Mar 2020
- May 1, 20208-KCurrent reportMaterial agreement · Regulation FD disclosure · Other events
Official filings of Vivus with the US Securities and Exchange Commission.
Annual results
- Revenue
- $70 M
- Operating income
- $-11 M
- Net income
- $-32 M
For year ending December-2019 · source: SEC filing
Balance sheet
- Total assets
- $218 M
- Total liabilities
- $288 M
- Total equity
- $-69 M
As of December-2019
Insider trading at Vivus#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Santosh T. VargheseChief Medical Officer | Grant or award | +700 | $2.380 | $2 K | 9,242 | Form 4 |
| filed | Mark K. OkiSVP, CFO, CAO | Grant or award | +700 | $2.380 | $2 K | 12,100 | Form 4 |
| filed | Mark K. OkiSVP, CFO, CAO | Grant or award | +700 | $2.840 | $2 K | 11,400 | Form 4 |
| filed | Santosh T. VargheseChief Medical Officer | Grant or award | +700 | $2.840 | $2 K | 8,542 | Form 4 |
| filed | John P. AmosChief Executive Officer, Director | Buyamended | +11,000 | $4.850 | $53 K | 181,850 | Form 4/A |
| filed | John P. AmosChief Executive Officer, Director | Buy | +11,000 | $4.850 | $53 K | 1.72 M | Form 4 |
| filed | Eric W. RobertsDirector | Buy | +8,500 | $4.820 | $41 K | 16,660 | Form 4 |
| filed | Santosh T. VargheseChief Medical Officer | Grant or award | +700 | $2.710 | $2 K | 7,842 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Vivus#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 10-for-1 split
Bankruptcy filing: (8-K)
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Vivus scorecard#
Passes 3 of the 13 checks that could be worked out: strongest in growth (2 of 6), weakest in financial health (0 of 3). Fiscal year 2019.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth2 of 6
- ✓Revenue grew in the newest year7.2%Revenue up 7.2% in fiscal 2019.
- ✗Revenue up more than 5% a year over three years-17.5%-17.5% a year over the three years to fiscal 2019.
- ✗Faster growth over three years than its peers' median-17.5%-17.5% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-2.96 vs -3.48Diluted EPS -2.96 in fiscal 2019 against -3.48 the year before (report's currency).
- ✓Net income higher than five years earlier-$32 M-$32 M in fiscal 2019 against -$83 M in 2014.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2019.
Profitability1 of 4
- ✗Profitable in the newest year-$32 MNet income -$32 M in fiscal 2019.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2019.
- ✓Operating margin above its peers' median-15.7%-15.7% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-15.7%-15.7% in fiscal 2019 against 44.8% in 2016.
Financial health0 of 3
- ✗Short-term assets cover short-term liabilities0.4×Current ratio 0.43 at the end of fiscal 2019.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- ✗Net debt below three years of EBITDA56.0×Net debt 56.0 times EBITDA in fiscal 2019.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2019.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Vivus: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 | FY 2015to Dec 31, 2015 | FY 2014to Dec 31, 2014 | FY 2013to Dec 31, 2013 | FY 2012to Dec 31, 2012 | FY 2011to Dec 31, 2011 | FY 2010to Dec 31, 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 70+7.2%100% | 65−0.5%100% | 65−47.4%100% | 124+30.2%100% | 95−16.4%100% | 114+40.8%100% | 81+3930%100% | 2.0—100% | — | — | |
| Cost of revenue | 16+7.2%22.5% | 15−12.2%22.5% | 17r17+68.5%25.5% | 9.9r11−71.1%7.9% | 34+2.3%35.8% | 33+586%29.2% | 4.9+2503%6.0% | 0.2—9.3% | — | — | |
| Research and development | 10+42.5%15.0% | 7.3+39.6%11.3% | 5.3−5.9%8.1% | 5.6−44.6%4.5% | 10−26.8%10.6% | 14−53.5%12.1% | 30−7.4%36.6% | 32+30.3%1594% | 25−38.4%— | 40—— | |
| Selling, general and administrative | — | 38−5.5%58.3% | 40−23.4%61.4% | 52−34.0%42.2% | 79−28.8%83.2% | 112−29.5%97.7% | 158+44.3%195% | 110+388%5451% | 22—— | — | |
| Selling and marketing | 18+28.6%25.8% | 14−16.0%21.5% | 17—25.5% | — | — | — | — | — | — | — | |
| General and administrative | 22−7.9%31.6% | 24+2.0%36.8% | 23—35.9% | — | — | — | — | 110+388%5451% | 22−12.4%— | 26—— | |
| Operating expenses | — | 69+9.5%105% | 63−8.7%95.7% | 69−56.0%55.2% | 156−5.6%163% | 165−30.0%144% | 236+66.1%291% | 142+201%7054% | 47−28.3%— | 66—— | |
| Total costs and expenses | 81+17.8%116% | 69+9.5%105% | 63—95.7% | — | — | — | — | — | — | — | |
| Operating income | −11—−15.7% | −3.5−225%−5.3% | 2.8−95.0%4.3% | 56—44.8% | −60—−63.2% | −51—−44.4% | −155—−191% | −140—−6954% | −47—— | −66—— | |
| Interest and finance income | — | — | — | — | — | — | — | 0.2−17.1%9.9% | 0.2r0.2−48.7%— | 0.5—— | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | 0.0−99.9%— | 4.3—— | |
| Net interest income | — | — | — | — | — | −33—−28.5% | −20−9915%−24.1% | 0.2−17.1%9.9% | 0.2—— | — | |
| Other non-operating income (expense) | −21—−29.4% | −33—−51.4% | −33—−50.9% | −32—−26.0% | −33—−34.4% | −33—−28.5% | −20−10268%−25.0% | 0.2−17.1%9.9% | 0.2—— | −9.8—— | |
| Income before tax | −31—−45.1% | −37—−56.7% | −31−231%−46.7% | 23—18.8% | −93—−97.6% | −83—−72.9% | −175—−216% | −140—−6944% | −47—— | −75—— | |
| Income tax | 0.0−59.6%0.0% | 0.1+2500%0.1% | 0.0−97.1%0.0% | 0.1+2233%0.1% | 0.0—0.0% | −0.6−748%−0.6% | 0.1+259%0.1% | 0.0−85.8%1.3% | 0.2+2011%— | 0.0—— | |
| Income from continuing operations | −32—−45.2% | −37—−56.8% | −31−231%−46.7% | 23—18.8% | −93—−97.6% | −83—−72.4% | −175—−216% | −140—−6945% | −47—— | −75—— | |
| Income from discontinued operations | — | — | — | — | — | — | 0.5—0.6% | −0.1−117%−7.4% | 0.9−90.5%— | 9.4—— | |
| Net income attributable to shareholders | −32—−45.2% | −37—−56.8% | −31−231%−46.7% | 23—18.8% | −93—−97.6% | −83—−72.4% | −174—−215% | −140—−6952% | −46—— | −66—— | |
| Earnings per share, basic | -2.96—— | -3.48—— | -2.89r-0.29−230%— | 2.23r0.22—— | -0.90—— | -0.80—— | -1.72—— | -1.42—— | -0.55—— | -0.82—— | |
| Earnings per share, diluted | -2.96—— | -3.48—— | -2.89r-0.29−230%— | 2.22r0.22—— | -0.90—— | -0.80—— | -1.72—— | -1.42—— | -0.55—— | -0.82—— | |
| Shares, weighted average (basic) | — | 11+0.4%— | 11r106+1.3%— | 10r104−90.0%— | 104+0.5%— | 103—— | — | 98+16.5%— | 84+4.2%— | 81—— | |
| Shares, weighted average (diluted) | 11+0.2%— | 11+0.4%— | 11r106+0.7%— | 10r105−89.9%— | 104+0.5%— | 103+2.3%— | 101+2.9%— | 98+16.5%— | 84+4.2%— | 81—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 33+7.4%15.0% | 30−54.2%10.1% | 66−21.7%25.1% | 85−11.1%27.7% | 95+14.7%34.4% | 83−19.5%22.7% | 103+76.2%23.9% | 59+48.2%22.2% | 40+6.3%26.0% | 37—25.8% | |
| Short-term investments | 0−100%0.0% | 81−49.5%26.8% | 160−13.4%60.4% | 185+26.4%60.4% | 146−32.5%52.7% | 216—59.0% | — | — | — | — | |
| Receivables | 22−12.8%10.2% | 26+110%8.5% | 12+28.6%4.6% | 9.5+5.3%3.1% | 9.0−22.4%3.2% | 12−5.1%3.2% | 12+340%2.8% | 2.8—1.1% | — | — | |
| Inventory | 34+45.6%15.4% | 23+30.6%7.7% | 18+9.4%6.7% | 16+19.0%5.3% | 14−60.5%4.9% | 34−29.0%9.4% | 49+91.3%11.2% | 25+716%9.6% | 3.1−3.7%2.0% | 3.2—2.2% | |
| Other current assets | 8.1+7.9%3.7% | 7.5+5.0%2.5% | 7.2−13.0%2.7% | 8.3−12.5%2.7% | 9.4r11−26.5%3.4% | 13−35.7%3.5% | 20+4.1%4.6% | 19r19+969%7.3% | 1.8+8.8%1.2% | 1.6—1.1% | |
| Current assets | 97−42.2%44.3% | 168−36.4%55.4% | 263−13.2%99.4% | 303+10.9%99.2% | 274r275−23.7%98.7% | 358−15.5%97.7% | 424+61.9%98.2% | 262r262+72.6%99.2% | 152+5.3%99.8% | 144—99.8% | |
| Property, plant and equipment | 0.2−31.7%0.1% | 0.3−37.1%0.1% | 0.5−31.2%0.2% | 0.8−20.7%0.3% | 1.0−26.2%0.4% | 1.3−31.1%0.4% | 2.0+0.2%0.5% | 2.0+510%0.7% | 0.3+44.8%0.2% | 0.2—0.2% | |
| Right-of-use (leased) assets | 0.8—0.4% | — | — | — | — | — | — | — | — | — | |
| Other intangible assets | 120−10.9%54.7% | 134—44.4% | — | — | — | — | — | — | — | — | |
| Non-current assets | — | — | — | — | — | 7.2+21.3%1.9% | 5.9+1956%1.4% | 0.3—0.1% | — | — | |
| Total assets | 218−27.7%100% | 302+14.0%100% | 265−13.3%100% | 306+10.3%100% | 277r281−24.5%100% | 367−15.0%100% | 432+63.5%100% | 264+73.7%100% | 152+5.4%100% | 144—100% | |
| Accounts payable | 7.7−13.4%3.5% | 8.9−11.4%3.0% | 10+114%3.8% | 4.7−33.3%1.5% | 7.1−32.3%2.5% | 10−3.1%2.8% | 11−57.6%2.5% | 25+763%9.6% | 2.9+22.8%1.9% | 2.4—1.7% | |
| Debt due within a year | 183—83.8% | — | 5.1−40.9%1.9% | 8.7−39.3%2.8% | 14r16+37.3%5.2% | 10—2.9% | 0—0.0% | — | — | — | |
| Current liabilities | 225+421%103% | 43+11.4%14.3% | 39−19.7%14.6% | 48−18.8%15.8% | 59r61+4.9%21.4% | 57r57+8.9%15.4% | 52+26.2%12.0% | 41+276%15.6% | 11−10.7%7.2% | 12—8.5% | |
| Long-term debt | 59−80.1%26.9% | 294+27.7%97.5% | 231−0.9%87.0% | 233+7.2%76.1% | 217r219−0.1%78.3% | 217+2.0%59.2% | 213—49.4% | — | — | — | |
| Lease liabilities (non-current) | 0.5—0.2% | — | — | — | — | — | — | — | — | — | |
| Total liabilities | 288−16.0%132% | 342+24.7%113% | 274−4.6%104% | 288+1.2%94.1% | 284r288−0.0%103% | 284+2.2%77.5% | 278+576%64.5% | 41—15.6% | — | — | |
| Retained earnings | −912—−418% | −881—−291% | −844—−318% | −813—−266% | −836—−302% | −743—−203% | −661—−153% | −486—−184% | −346—−228% | −300—−208% | |
| Shareholders' equity | −69—−31.7% | −40—−13.2% | −9.3−151%−3.5% | 18—5.9% | −7.1−109%−2.6% | 83−46.2%22.5% | 153−31.2%35.5% | 223+58.0%84.4% | 141+6.9%92.8% | 132—91.5% | |
| Total equity | — | — | — | — | — | — | — | — | — | 132—91.5% | |
| Total liabilities and equity | 218−27.7%100% | 302+14.0%100% | 265−13.3%100% | 306+10.3%100% | 277r281−24.5%100% | 367−15.0%100% | 432+63.5%100% | 264+73.7%100% | 152+5.4%100% | 144—100% | |
| Shares outstanding | 11+0.1%— | 11+0.3%— | 11r106−89.9%— | 105+0.8%— | 104+0.3%— | 104+0.6%— | 103+2.5%— | 101+13.1%— | 89+9.1%— | 82—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 15+65.7%21.1% | 8.9+994%13.6% | 0.8−24.9%1.2% | 1.1−22.1%0.9% | 1.4+24.7%1.5% | 1.1—1.0% | — | — | — | — | |
| Share-based compensation | 2.0−38.3%2.9% | 3.3+11.7%5.0% | 2.9+28.8%4.5% | 2.3−36.4%1.8% | 3.6−63.2%3.8% | 9.8−69.9%8.6% | 32+103%40.0% | 16+117%792% | 7.4+14.1%— | 6.4—— | |
| Cash from operating activities | −30—−43.7% | −24—−36.3% | −16−143%−25.0% | 38—30.7% | −46—−48.6% | −38—−33.4% | −135—−167% | −132r−132—−6556% | −37r−40—— | −64r−66—— | |
| Capital expenditure | −0.0—−0.1% | −0.0—−0.1% | −0.0—−0.0% | −0.2—−0.2% | −0.3—−0.3% | −0.3—−0.2% | −1.8—−2.2% | −1.7—−83.0% | −0.2—— | −0.1—— | |
| Cash from investing activities | 82—117% | −56−334%−86.3% | 24—36.7% | −40−159%−32.3% | 67+324%70.6% | 16—13.9% | −90—−111% | −55r−54—−2714% | −8.6r−5.5−110%— | 85r86—— | |
| Cash from financing activities | −49−212%−70.0% | 44—67.3% | −26—−39.8% | −8.7—−7.0% | −8.9−517%−9.3% | 2.1−99.2%1.9% | 270+31.4%333% | 206+330%10217% | 48—— | −24—— | |
| Exchange-rate effect on cash | −0.0—−0.1% | — | — | — | — | — | — | — | — | — | |
| Change in cash | 2.2—3.2% | −36—−55.3% | −18—−28.1% | −11−187%−8.5% | 12—12.8% | −20−145%−17.6% | 45+134%55.1% | 19+715%947% | 2.3—— | −3.3—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Mar 31, 2020 | Q1 FY2020to Mar 31, 2020 | Q4 FY2019to Dec 31, 2019 | Q3 FY2019to Sep 30, 2019 | Q2 FY2019to Jun 30, 2019 | Q1 FY2019to Mar 31, 2019 | Q4 FY2018to Dec 31, 2018 | Q3 FY2018to Sep 30, 2018 | Q2 FY2018to Jun 30, 2018 | Q1 FY2018to Mar 31, 2018 | Q4 FY2017to Dec 31, 2017 | Q3 FY2017to Sep 30, 2017 | Q2 FY2017to Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 73+5.7%100% | 20+21.6%100% | 17−14.2%100% | 18−0.7%100% | 18+22.9%100% | 16+35.7%100% | 20+68.4%100% | 18+19.1%100% | 15+33.3%100% | 12—100% | 12—100% | 15—100% | 11—100% | |
| Cost of revenue | 16−1.8%21.8% | 4.6+7.4%23.6% | 4.0*−23.8%23.0% | 3.0−13.4%16.8% | 4.4+33.2%23.8% | 4.3+63.8%26.7% | 5.2*+18.8%25.9% | 3.5+1.8%19.3% | 3.3−3.0%22.0% | 2.6r2.7—22.1% | 4.4r3.9*—36.8% | 3.4r3.5—22.5% | 3.4r3.6—30.2% | |
| Gross profit | — | — | 13−10.9%77.0% | 15+2.4%83.2% | 14+20.0%76.2% | 12+27.7%73.3% | 15+86.1%74.1% | 15+25.0%80.7% | 12+52.5%78.0% | 9.3—77.9% | 8.0—67.0% | 12—76.9% | 7.7—68.2% | |
| Research and development | 10+24.1%14.3% | 2.4−1.0%12.5% | 2.4*+32.2%13.8% | 3.3+55.4%18.2% | 2.4+15.2%12.8% | 2.5+76.0%15.3% | 1.8*+49.5%8.9% | 2.1+143%11.6% | 2.0+101%13.6% | 1.4—11.8% | 1.2*—10.1% | 0.9—5.7% | 1.0—9.0% | |
| Selling, general and administrative | — | — | — | — | — | — | 7.7*−11.2%38.3% | 8.5+0.8%46.7% | 12+0.7%78.3% | 10—84.6% | 8.7*—72.7% | 8.4—55.2% | 12—104% | |
| Selling and marketing | 18+24.2%24.1% | 4.2−6.6%21.6% | 4.3*+40.3%25.0% | 4.5+45.8%25.1% | 4.6+30.8%25.1% | 4.5+6.0%28.1% | 3.1*—15.3% | 3.1—17.1% | 3.5—23.5% | 4.3—36.0% | — | — | — | |
| General and administrative | 24+0.2%32.1% | 6.7+27.3%34.3% | 6.6*+43.2%38.4% | 4.7−12.4%26.1% | 5.5−33.3%29.7% | 5.3−8.7%32.7% | 4.6*—23.0% | 5.4—29.6% | 8.2—54.7% | 5.8—48.6% | — | — | — | |
| Operating expenses | — | — | 21+14.0%121% | 19+8.2%106% | 20+11.6%111% | 20+42.6%125% | 18+32.8%91.3% | 18+38.5%97.7% | 18+12.9%122% | 14—119% | 14—116% | 13—84.0% | 16—144% | |
| Total costs and expenses | 82+10.2%112% | 22+7.1%110% | 21*+14.0%121% | 19+8.2%106% | 20+11.6%111% | 20—125% | 18*—91.3% | 18—97.7% | 18—122% | — | — | — | — | |
| Operating income | −8.9—−12.2% | −2.0—−10.4% | −3.7*−309%−21.3% | −1.2−384%−6.4% | −2.0—−11.1% | −4.1—−25.3% | 1.8*—8.7% | 0.4−83.2%2.3% | −3.4—−22.4% | −2.3—−19.3% | −1.9*—−15.7% | 2.4—16.0% | −5.0—−44.4% | |
| Other non-operating income (expense) | −20—−27.1% | −3.2—−16.4% | −2.9*—−16.5% | −9.9—−55.2% | −3.9—−21.1% | −3.9—−24.0% | −6.3*—−31.1% | −9.6—−53.0% | −9.2—−61.6% | −8.3—−70.2% | −8.2*—−68.6% | −8.4—−55.4% | −8.4—−74.8% | |
| Income before tax | −29—−39.3% | −5.3—−26.8% | −6.5*—−37.8% | −11—−61.6% | −5.9—−32.2% | −8.0—−49.3% | −4.5*—−22.4% | −9.2—−50.8% | −13—−84.0% | −11—−89.4% | −10*—−84.3% | −6.0—−39.4% | −13—−119% | |
| Income tax | −0.0−150%−0.0% | −0.0—−0.2% | 0.0*—0.1% | 0.0−88.9%0.0% | 0.0+100%0.0% | −0.0−167%−0.0% | 0*−100%0.0% | 0.0+350%0.2% | 0.0+300%0.0% | 0.0—0.1% | 0.0*—0.0% | 0.0—0.1% | 0.0—0.0% | |
| Income from continuing operations | — | — | −6.5—−37.9% | −11—−61.6% | −5.9—−32.3% | −7.9—−49.2% | −4.5—−22.4% | −9.2—−51.0% | −13—−84.1% | −11—−89.5% | −10—−84.4% | −6.0—−39.5% | −13—−119% | |
| Net income attributable to shareholders | −29—−39.3% | −5.2—−26.6% | −6.5*—−37.9% | −11—−61.6% | −5.9—−32.3% | −7.9—−49.2% | −4.5*—−22.4% | −9.2—−51.0% | −13—−84.1% | −11—−89.5% | −10*—−84.4% | −6.0—−39.5% | −13—−119% | |
| Earnings per share, basic | -2.70—— | -0.49—— | -0.61—— | -1.04—— | -0.56—— | -0.75—— | -0.42—— | -0.87—— | -1.18r-0.12—— | -1.00r-0.10—— | -0.95r-0.10—— | -0.57r-0.06—— | -1.27r-0.13—— | |
| Earnings per share, diluted | -2.70—— | -0.49—— | -0.61—— | -1.04—— | -0.56—— | -0.75—— | -0.42—— | -0.87—— | -1.18r-0.12—— | -1.00r-0.10—— | -0.95r-0.10—— | -0.57r-0.06—— | -1.27r-0.13—— | |
| Shares, weighted average (diluted) | 11+0.1%— | 11+0.1%— | — | 11+0.1%— | 11+0.3%— | 11+0.3%— | — | 11+0.4%— | 11r106−90.0%— | 11r106—— | — | 11r106—— | 106—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 33—15.2% | 33+42.7%15.2% | 33+7.4%15.0% | 40−30.9%17.7% | 25−56.2%8.8% | 23−70.0%7.9% | 30−54.2%10.1% | 58−20.7%18.9% | 57−25.2%18.7% | 77—30.8% | 66—25.1% | 73—27.4% | 76—27.0% | |
| Short-term investments | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 69+4.5%24.4% | 82−38.3%28.1% | 81−49.5%26.8% | 57−64.9%18.6% | 66−62.1%21.7% | 132—53.1% | 160—60.4% | 163—61.1% | 175—61.9% | |
| Receivables | 25—11.5% | 25+0.7%11.5% | 22−12.8%10.2% | 24+1.9%10.6% | 25+122%8.6% | 25+117%8.5% | 26+110%8.5% | 24+100%7.7% | 11+31.2%3.6% | 11—4.5% | 12—4.6% | 12—4.4% | 8.4—3.0% | |
| Inventory | 34—15.7% | 34+54.6%15.7% | 34+45.6%15.4% | 30+38.9%13.3% | 30+35.3%10.6% | 22+4.5%7.6% | 23+30.6%7.7% | 22+60.7%7.1% | 22+42.4%7.3% | 21—8.4% | 18—6.7% | 13—5.0% | 16—5.5% | |
| Other current assets | 6.3—2.9% | 6.3−3.5%2.9% | 8.1+7.9%3.7% | 7.0−9.9%3.1% | 7.0+8.9%2.4% | 6.6+1.9%2.3% | 7.5+5.0%2.5% | 7.7+106%2.5% | 6.4+20.0%2.1% | 6.4—2.6% | 7.2—2.7% | 3.8—1.4% | 5.3—1.9% | |
| Current assets | 98—45.3% | 98−38.0%45.3% | 97−42.2%44.3% | 101−39.8%44.7% | 156−4.4%54.8% | 158−36.4%54.4% | 168−36.4%55.4% | 168−36.6%54.9% | 163−41.9%53.5% | 248—99.4% | 263—99.4% | 265—99.4% | 281—99.3% | |
| Property, plant and equipment | 0.2—0.1% | 0.2−38.2%0.1% | 0.2−31.7%0.1% | 0.3−28.3%0.1% | 0.3−31.2%0.1% | 0.3−36.3%0.1% | 0.3−37.1%0.1% | 0.4−37.1%0.1% | 0.4−33.6%0.1% | 0.5—0.2% | 0.5—0.2% | 0.6—0.2% | 0.7—0.2% | |
| Right-of-use (leased) assets | 0.7—0.3% | 0.7−39.0%0.3% | 0.8—0.4% | 0.9—0.4% | 1.0—0.3% | 1.1—0.4% | — | — | — | — | — | — | — | |
| Other intangible assets | 116—53.7% | 116−11.2%53.7% | 120−10.9%54.7% | 123−10.6%54.5% | 127−10.3%44.5% | 130—44.9% | 134—44.4% | 138—44.9% | 141—46.3% | — | — | — | — | |
| Total assets | 216—100% | 216−25.6%100% | 218−27.7%100% | 226−26.2%100% | 285−6.8%100% | 290+16.4%100% | 302+14.0%100% | 306+14.9%100% | 305+7.9%100% | 249—100% | 265—100% | 267—100% | 283—100% | |
| Accounts payable | 11—5.1% | 11+205%5.1% | 7.7−13.4%3.5% | 6.2+37.4%2.7% | 3.8−12.5%1.3% | 3.6−24.5%1.2% | 8.9−11.4%3.0% | 4.5+1.2%1.5% | 4.3−0.9%1.4% | 4.8—1.9% | 10—3.8% | 4.4—1.7% | 4.4—1.6% | |
| Debt due within a year | 182—84.2% | 182—84.2% | 183—83.8% | 184—81.5% | 185—65.1% | — | — | — | — | 0.8—0.3% | 5.1—1.9% | 9.4—3.5% | 25—8.7% | |
| Current liabilities | 228—106% | 228+485%106% | 225+421%103% | 227+488%100% | 225+581%79.2% | 39+36.3%13.4% | 43+11.4%14.3% | 39+8.7%12.6% | 33−35.1%10.9% | 29—11.5% | 39—14.6% | 35—13.3% | 51—18.0% | |
| Long-term debt | 59—27.3% | 59−79.9%27.3% | 59−80.1%26.9% | 59−80.5%25.9% | 107−63.8%37.6% | 293+24.5%101% | 294+27.7%97.5% | 300+33.2%98.0% | 295+34.2%96.8% | 236—94.5% | 231—87.0% | 225—84.5% | 220—77.9% | |
| Lease liabilities (non-current) | 0.3—0.2% | 0.3−62.4%0.2% | 0.5—0.2% | 0.6—0.3% | 0.7—0.3% | 0.9—0.3% | — | — | — | — | — | — | — | |
| Total liabilities | 290—134% | 290−14.1%134% | 288−16.0%132% | 289−15.6%128% | 337+1.2%118% | 337+25.5%116% | 342+24.7%113% | 343+28.6%112% | 333+20.1%109% | 269—108% | 274—104% | 266—99.9% | 277—98.1% | |
| Retained earnings | −917—−425% | −917—−425% | −912—−418% | −905—−400% | −894—−314% | −888—−306% | −881—−291% | −876—−286% | −867—−284% | −854—−343% | −844—−318% | −833—−312% | −827—−293% | |
| Shareholders' equity | −74—−34.3% | −74—−34.3% | −69—−31.7% | −63—−28.0% | −52—−18.4% | −47—−16.3% | −40—−13.2% | −36−10326%−11.8% | −28−610%−9.1% | −20—−7.8% | −9.3—−3.5% | 0.4—0.1% | 5.5—1.9% | |
| Total liabilities and equity | 216—100% | 216−25.6%100% | 218−27.7%100% | 226−26.2%100% | 285−6.8%100% | 290+16.4%100% | 302+14.0%100% | 306+14.9%100% | 305+7.9%100% | 249—100% | 265—100% | 267—100% | 283—100% | |
| Shares outstanding | 11—— | 11+0.1%— | 11+0.1%— | 11+0.1%— | 11−90.0%— | 11−90.0%— | 11+0.3%— | 11−90.0%— | 106+0.4%— | 106—— | 11r106—— | 106—— | 106—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 15+18.6%20.1% | 3.7−0.1%18.7% | 3.7*0.0%21.3% | 3.7*−0.8%20.4% | 3.7*+175%20.0% | 3.7+2241%22.8% | 3.7*+2273%18.3% | 3.7*+2288%20.5% | 1.3*+437%8.9% | 0.2—1.3% | 0.2*—1.3% | 0.2*—1.0% | 0.2*—2.2% | |
| Share-based compensation | 1.9−33.0%2.6% | 0.3−27.8%1.7% | 0.6*−4.3%3.5% | 0.5−28.6%2.7% | 0.5−55.5%2.5% | 0.5−49.4%2.9% | 0.6*−11.9%3.2% | 0.7−10.2%3.7% | 1.0+41.6%7.0% | 0.9—7.8% | 0.7*—6.0% | 0.8—5.0% | 0.7—6.6% | |
| Cash from operating activities | −23—−32.0% | 0.1—0.6% | −7.4*−342%−42.9% | −5.6*—−31.4% | −11*—−57.1% | −6.9—−43.0% | 3.1*—15.2% | −8.5*—−47.2% | −6.1*—−41.1% | −12—−101% | −4.9*—−40.9% | −0.2*—−1.3% | −4.2*—−37.6% | |
| Capital expenditure | — | — | 0*—0.0% | −0.0*—−0.0% | −0.0*—−0.1% | −0.0—−0.1% | 0*—0.0% | 0*—0.0% | 0*—0.0% | −0.0—−0.3% | 0*—0.0% | 0*—0.0% | 0*—0.0% | |
| Cash from investing activities | — | — | 0*—0.0% | 69*+642%386% | 13*—68.4% | −0.5−102%−2.8% | −24*−1074%−117% | 9.4*−23.4%51.7% | −69*−499%−461% | 27—227% | 2.4*—20.2% | 12*—80.3% | 17*—154% | |
| Cash from financing activities | — | −0.1—−0.3% | −0.0*—−0.2% | −49*−256421%−271% | — | — | −7.1*—−35.5% | 0.0*—0.1% | 55*—371% | −4.6—−38.6% | −4.3*—−36.0% | −15*—−100% | −4.4*—−39.2% | |
| Exchange-rate effect on cash | — | 0.1—0.7% | −0.0*—−0.2% | — | — | — | — | — | — | — | — | — | — | |
| Change in cash | — | 0.2—1.0% | −7.5*—−43.3% | — | — | −7.4−171%−45.8% | −28*—−137% | 0.8*—4.6% | −20*−327%−131% | 10—87.5% | −6.8*—−56.6% | −3.3*—−21.4% | 8.7*—77.1% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Mar 31, 2020. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Vivus#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Bankruptcy or receivership 1 · Delisting notice 1 · Debt called early 2 · Directors and officers 5 · Material agreement 7 · Shareholder rights changed 1 · Results announced 6
| Filed | What happened | Filing |
|---|---|---|
| Delisting notice | 8-K | |
| Bankruptcy or receivershipDebt called earlyDirectors and officersMaterial agreement | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Debt called earlyMaterial agreement | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Material agreementShareholder rights changed | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersMaterial agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Jul 13, 2020
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2013 | · | · | · | · | · | · | · | · | · | 20 | · | · | 20 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 20 people | Restructuring planSEC 8-K | “Costs Associated with Exit or Disposal Activities On October 30, 2013, as part of the Company’s ongoing efforts to reduce costs by eliminating expenses that are not essential to ex…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Vivus compares in Biotechnology
- Revenue$70 M · higher than 64% of 647
- Net margin-45.1% · higher than 52% of 408
- Revenue growth7.2% · higher than 50% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Vivus🇺🇸 | $29 M | — | -45.1% | +7.2% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 1, 2020 (last known)
- Annual results:
- For year ending December-2019
- Balance sheet:
- As of December-2019
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, Wikidata, Wikipedia, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Vivus? Verify and update this profile — free
Show Vivus's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.